Johnson & Johnson (JNJ) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal second quarter ended June 30, 2024. Johnson & Johnson operates as a large accelerated filer with two primary business segments: Innovative Medicine and MedTech. The Consumer Health business (Kenvue) was separated in 2023 and is reported as discontinued operations. The company completed the acquisition of Shockwave Medical Inc. on May 31, 2024, and subsequently acquired Yellow Jersey Therapeutics and Proteologix, Inc. in July 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Sales to Customers | $22.45 Billion | $21.52 Billion | $43.83 Billion | $42.41 Billion |
| Net Earnings | $4.69 Billion | $5.14 Billion | $7.94 Billion | $5.08 Billion |
| Diluted EPS (Continuing Ops) | $1.93 | $2.05 | $3.27 | $1.86 |
| Gross Margin | 69.4% | 70.0% | 69.5% | 69.0% |
| Operating Cash Flow (YTD) | $9.29 Billion | |||
| Total Debt (Current + Long-term) | $41.49 Billion | |||
| Cash & Cash Equivalents | $24.88 Billion |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 4.3% in Q2 2024 and 3.3% YTD, driven by operational growth of 6.6% (Q2) and 5.2% (YTD), partially offset by negative currency impacts of 2.3% and 1.9%, respectively.
- Segment Performance:
- Innovative Medicine: Sales grew 5.5% in Q2 and 3.3% YTD. Growth was led by Oncology (15.7% Q2 growth) and Immunology (5.0% Q2 growth), offset by declines in Infectious Diseases due to the cessation of COVID-19 vaccine revenue.
- MedTech: Sales grew 2.2% in Q2 and 3.3% YTD. The Cardiovascular franchise saw significant growth (15.6% Q2) driven by the Shockwave acquisition and strong Electrophysiology performance.
- Profitability: Net earnings decreased in Q2 2024 compared to Q2 2023, primarily due to higher litigation charges and acquisition-related costs. However, YTD net earnings increased significantly ($7.94B vs $5.08B) due to a massive $7.0 billion talc-related charge in the prior year that was not repeated in the same magnitude in 2024.
- Acquisitions: The company recorded $14.8 billion in cash used for acquisitions YTD, primarily for Shockwave Medical ($13.1B enterprise value).
Guidance, Outlook, and Risks
- Talc Litigation: The company recorded a $3.0 billion charge in the first six months of 2024 related to talc matters. A proposed "prepackaged" bankruptcy plan for LTL Management LLC (the entity holding talc liabilities) is being solicited, with a present value reserve of approximately $6.475 billion. The total reserve as of June 30, 2024, is approximately $10.6 billion.
- Opioid Litigation: Approximately 70% of the $5.0 billion opioid settlement has been paid. Remaining claims are being defended.
- Patent Expirations: The company faces biosimilar competition for key products like REMICADE and STELARA (U.S. launch expected Jan 1, 2025). XARELTO sales declined due to share loss and patient mix.
- Outlook: Management expects operating cash flows and access to capital markets to fund operations and litigation settlements. The company anticipates the effective tax rate for 2024 to increase by 1.0% to 1.5% due to Pillar Two legislation and non-deductible acquisition expenses.
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the $10.6 billion reserve against the proposed $6.475 billion settlement plan and ongoing litigation risks.
- Shockwave Integration: Monitor the integration progress and revenue contribution of the Shockwave Medical acquisition in the MedTech segment.
- Biosimilar Impact: Track sales trends for STELARA and REMICADE as biosimilar competition intensifies in 2024 and 2025.
- Effective Tax Rate: Confirm the impact of Pillar Two legislation and non-deductible R&D impairments on the full-year effective tax rate.
- COVID-19 Vaccine Run-off: Assess the full-year impact of the complete cessation of COVID-19 vaccine revenue on the Infectious Diseases portfolio.